Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
SII.TO 3.52IPCO.TO -0.15DC.A.TO 0.3NESN-SIX 0MCK 13.94GOOG -1.34XLV 0.79TEVA 0.65
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.44
+0.47 (1.66%)
as of Aug 25, 2026, 6:15:49 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
DON'T BUY

Pfizer Inc(PFE)

Oct 28, 2021
Has tended to peak out at 4x book value, around $50. Vaccine potential has petered out. FMV potential is 55% higher than current price. More likely to have a further setback, with $37-38 as his downside target. The stock's already given at the office and it's not prepared to give at home.
Photo of Ross HealyRoss HealyUnlock Rating
$43.14

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
BUY

Pfizer Inc(PFE)

Oct 18, 2021
All healthcare stocks have been pressured. PFE is protected by their near-4% dividend. We will all need their Covid booster shot.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$41.32

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Oct 04, 2021
The performance has been disappointing. The problem with big, old pharma is that it is not enough to move the needle. He thinks it is a good one to put away. They are a little constrained on the new product side. He'd suggest an ETF of biotech companies.
Photo of John ZechnerJohn ZechnerUnlock Rating
$42.42

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 30, 2021
Great dividend yield, not trading at a high multiple. Not a pure play. Covid vaccine issue will continue for years to come. Likes healthcare, but it tends to come up as a US political issue. A great story here. He owns JNJ instead.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$43.44

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Sep 22, 2021
Good quality stock that won't hurt you. Reasonable valuation, nice dividend. Bad news is everything is already built into the stock. Where's the growth past 2023? Not much upside. He'd add at $32-36, but not here at $44.
Photo of Greg NewmanGreg NewmanUnlock Rating
$44.27

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 17, 2021
A broad company with many types of drugs. Laws in the US stipulates that after spending millions of dollar for franchises, the drug will go off patent in time. Pharmaceuticals have been doing this for a long time.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$43.89

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 13, 2021
It looks good it will get FDA approval for a Covid vaccine for children. Any good news here will help PFE. He's owned this for a while. The current pullback is a buying opportunity.
Photo of Andrew PyleAndrew Pyle
Owned
Unlock Rating
$44.35

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 01, 2021

Many reasons to like this including booster shots which will help shares (though Moderna will benefit more). This has pulled back a but, she likes it here. Has value.

Photo of Karen FinermanKaren FinermanUnlock Rating
$46.04

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Aug 20, 2021
The New York Times reports that the FDA will give full approval to Pfizer's Covid vaccine (for booster shots). He wouldn't rush in after-hours to buy Pfizer, because he's wary of such after-hours moves. Such trading is thin, low-volume.
Photo of Brian KellyBrian KellyUnlock Rating
$48.72

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 18, 2021
It's been on a hot run. The Delta variant gives them a huge tailwind, because Washington is about to mandate Covid booster shots. Pfizer needs it, because they're about to lose the patents on some of their major drugs. Annual booster shots would give Pfizer a giant revenue stream. Shares are up 22% in the past month.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$49.31

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Pfizer Inc(PFE)

Aug 17, 2021
(A Top Pick Sep 24/20, Up 39%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PFE is progressing well. We now recommend trailing up the stop (from $33) to $42. If triggered this would all but guarantee a investment return over 17%, when including the previous recommendation to cover half.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$49.95

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 16, 2021
Likes it under $40-$36. A bit overbought right now. A good value play and dividend player but would not chase it here. There is probably limited upside here.
Photo of Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTA
No
Unlock Rating
$48.77

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 14, 2021

Opportunity for Pfizer and J&J are solid. You give up some appreciation when you select a stock with higher yield. However, total return is the most important. There is more diversification with JNJ with medical supplies. Pfizer's partnership with BioNtech is positive. There is renewed chatter about drug price controls. Both offer good prospective.

Photo of JoAnne FeeneyJoAnne FeeneyUnlock Rating
$40.08

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WAIT

Pfizer Inc(PFE)

Apr 30, 2021

They report Tuesday. Despite a successful Covid drug, the stock has done nothing because they have a slew of patents about to expire. That said, it's a fine stock with good managers and a safe dividend yield. You could do a lot worse. You would wait before the report.

Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$38.65

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 22, 2021

Not overly bullish on healthcare as a whole, as its growth may be less attractive. Likes medical devices, with a built-in backlog due to Covid. He owns SYK. There should be a significant pickup in procedures over the next 2 years. SYK has strong earnings growth, near a 1-year high. Also look at IHI, the medical devices ETF, packed with companies leading the healthcare sector.

Photo of David BurrowsDavid Burrows
No
Unlock Rating
$38.69

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 166 to 180 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NTR.TO -1.87$101
TFPM 0$
OGC.TO -0.31$42.91
SLB -0.3$53.7
ARG.TO 0.39$8.61

Today's Top Picks

SII.TO 3.52$190.71
IPCO.TO -0.15$35.07
DC.A.TO 0.3$5.45
NESN-SIX 0$
MCK 13.94$887.73

Popular Articles

Latest Sell Signals

RKLB -1.15$67.13
INTC 0.47$87.73
MSFT 2.5$489.81
WSP.TO -2.54$189.74
CLS.TO 7.17$414.53

Most Recent Experts

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like